Clinical Trials
24 trialsNivolumab and Ipilimumab in Treating Patients With Rare Tumors
National Cancer Institute (NCI)
Testing the Combination of Olaparib and Durvalumab, Cediranib and Durvalumab, Olaparib and Capivasertib, and Cediranib Alone in Recurrent or Refractory Endometrial Cancer Following the Earlier Phase of the Study That Tested Olaparib and Cediranib in Comparison to Cediranib Alone, and Olaparib Alone
National Cancer Institute (NCI)
Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma
National Cancer Institute (NCI)
Observational Study of Women With Endometrial Cancer Who Receive the Standard Treatment for Their Disease
Memorial Sloan Kettering Cancer Center
SENTIRAD
Centre Oscar Lambret
FRAME
Institute of Cancer Research, United Kingdom
ATARI
Institute of Cancer Research, United Kingdom
Sapanisertib and Serabelisib (PIKTOR) With Paclitaxel and a Substudy With an Insulin-Suppressing Diet in Patients With Advanced/Recurrent Endometrial Cancer
Faeth Therapeutics
Cabozantinib S-Malate in Treating Patients With Recurrent or Metastatic Endometrial Cancer
National Cancer Institute (NCI)
Study of STRO-002, an Anti-Folate Receptor Alpha (FolRα) Antibody Drug Conjugate in Ovarian & Endometrial Cancers
Sutro Biopharma, Inc.
Stereotactic Pelvic Adjuvant Radiation Therapy in Cancers of the Uterus.
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
PD-1 Inhibitor Combined With Progesterone Treatment in FST for Patients With MMRd Endometrial Cancer
Peking University People's Hospital
A Study to Evaluate ELU001 in Patients With Solid Tumors That Overexpress Folate Receptor Alpha (FRα)
Elucida Oncology
Fertility Sparing Therapy for Patients With Stage IA G2 Endometrial Cancer
Peking University People's Hospital
ACTOv
University College, London
Testing AZD1775 inC Combination With Radiotherapy and Chemotherapy in Cervical, Upper Vaginal and Uterine Cancers
National Cancer Institute (NCI)
Fertility-sparing Therapy for Patients With Stage IA Endometrial Cancer
Peking University People's Hospital
A Study to Evaluate Rucaparib in Combination With Nivolumab in Patients With Selected Solid Tumors (ARIES)
pharmaand GmbH
Copanlisib in Treating Patients With Persistent or Recurrent Endometrial Cancer
NRG Oncology
Abexinostat, Palbociclib, and Fulvestrant for the Treatment of Breast or Gynecologic Cancer
University of California, San Francisco
POEM
MedSIR
Dasatinib, Paclitaxel, and Carboplatin in Treating Patients With Stage III-IV or Recurrent Endometrial Cancer
National Cancer Institute (NCI)
EAOC
University Hospital, Basel, Switzerland
An Analysis of the Response of Human Tumor Microvascular Endothelium to Ionizing Radiation
Memorial Sloan Kettering Cancer Center